转移性肾细胞癌接受免疫治疗联合立体定向放疗或单纯免疫治疗的生存分析:美国国家癌症数据库分析
该研究基于美国国家癌症数据库,纳入644例接受一线免疫治疗(IO)的转移性肾细胞癌(mRCC)患者,其中63例(9.8%)联合立体定向放疗(SRT),581例(90.2%)单纯IO。IO+SRT组与IO组1年总生存(OS)分别为74.4%与65.0%,2年OS分别为71.0%与59.4%,差异未达统计学显著(log-rank P=.1077);在脑转移患者中,IO+SRT组1年OS(73.0% vs 54.7%)和2年OS(70.8% vs 51.4%)显著更高(pairwise P=.0261)。SRT时机(IO前或后)不影响OS(log-rank P=.3185)。
要点
- mRCC一线IO联合SRT与单纯IO相比,1年OS 74.4% vs 65.0%、2年OS 71.0% vs 59.4%,差异未达统计学显著(P=.1077)。
- 脑转移患者中IO+SRT组1年OS 73.0% vs 54.7%、2年OS 70.8% vs 51.4%,显著更高(pairwise P=.0261)。
- SRT在IO之前或之后进行不影响OS(log-rank P=.3185)。
核心结论
- mRCC继发脑转移患者接受IO联合SRT较单纯IO总生存延长。
- 作者认为未来分析应考虑IMDC风险分层、寡转移负荷、SRT剂量分割及双药联合治疗以更好识别可能从IO+SRT获益的患者。
- 作者指出需进一步开展前瞻性研究。
研究设计与样本
- 基于美国国家癌症数据库(NCDB)的分析,纳入接受一线IO±SRT的mRCC患者,IO alone队列允许接受常规放疗。
- 共644例 eligible 患者,63例(9.8%)接受IO+SRT,581例(90.2%)接受IO alone。
- 主要终点为按是否接受SRT分层的OS,次要终点为按脑转移及SRT时机(IO前或后)分层的OS。
- 生存采用Kaplan-Meier法估计,log-rank检验比较。
主要发现
- 中位随访17.7个月(范围2-24个月)。
- SRT治疗部位包括脑(71.4%)、肺/胸部(7.9%)、骨(7.9%)、脊柱(6.3%)及其他(6.3%)。
- IO+SRT组与IO alone组1年OS分别为74.4%与65.0%,2年OS分别为71.0%与59.4%,差异未达统计学显著(log-rank P=.1077)。
- 脑转移患者中,IO+SRT组与IO alone组1年OS分别为73.0%与54.7%,2年OS分别为70.8%与51.4%,IO+SRT组显著更高(pairwise P=.0261)。
- SRT时机(IO前或后)不影响OS(log-rank P=.3185)。
局限性
- 作者指出需进一步开展前瞻性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Immunotherapy (IO) has significantly improved outcomes in metastatic renal cell carcinoma (mRCC). Preclinical evidence suggests that responses to IO may be potentiated via immunomodulatory effects of stereotactic radiation therapy (SRT). We hypothesized that clinical outcomes from the National Cancer Database (NCDB) would demonstrate improved overall survival (OS) in patients with mRCC receiving IO + SRT versus IO alone. METHODS AND MATERIALS: Patients with mRCC receiving first-line IO ± SRT were identified from the NCDB. Conventional radiation therapy was allowed in the IO alone cohort. The primary endpoint was OS stratified by the receipt of SRT (IO + SRT vs IO alone). Secondary endpoints included OS stratified by the presence of brain metastases (BM) and timing of SRT (before or after IO). Survival was estimated using Kaplan-Meier methodology and compared via the log-rank test. RESULTS: Of 644 eligible patients, 63 (9.8%) received IO + SRT, and 581 (90.2%) received IO alone. Median follow-up time was 17.7 months (range, 2-24 months). Sites treated with SRT included the brain (71.4%), lung/chest (7.9%), bones (7.9%), spine (6.3%), and other (6.3%). OS was 74.4% versus 65.0% at 1 year and 71.0% versus 59.4% at 2 years for the IO + SRT and IO alone groups, respectively, although this difference did not reach statistical significance (log-rank P = .1077). In patients with BM, however, 1-year OS (73.0% vs 54.7%) and 2-year OS (70.8% vs 51.4%) was significantly higher in those receiving IO + SRT versus IO alone, respectively (pairwise P = .0261). Timing of SRT (before or after IO) did not influence OS (log-rank P = .3185). CONCLUSIONS: Patients with BM secondary to mRCC had prolonged OS with the addition of SRT to IO. Factors such as International mRCC Database Consortium risk stratification, oligometastatic tumor burden, SRT dose/fractionation, and utilization of doublet therapy should be considered in future analyses to better identify patients who may benefit from combined IO + SRT. Further prospective studies are warranted.
引用
- Piening A, Al-Hammadi N, Dombrowski J, et al. Survival in Metastatic Renal Cell Carcinoma Treated With Immunotherapy and Stereotactic Radiation Therapy or Immunotherapy Alone: A National Cancer Database Analysis. Adv Radiat Oncol. 2023. PMID: 37408680. doi:10.1016/j.adro.2023.101238
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。